Injectsense announces first human implant of ultraminiature IOP sensor

Digital health company Injectsense announced that it has successfully completed the first human implant and wireless IOP measurements using its ultraminiature implantable sensor, which has received FDA breakthrough designation.¹ The implant procedure was performed during the IOP-Connect system study by Juan Mura, MD, of the Centro de la Vision in Santiago, Chile, according to a news release.

“From a physician’s perspective, this is a major step toward understanding IOP fluctuations and providing more effective glaucoma treatment,” said Mura in the release. “It’s extremely exciting to have a direct path to an implantable sensor that will provide autonomous measurement 24/7.”

Injectsense now plans on fine-tuning the delivery tool for the sensor and to incorporate the Injectpower SAS solid-state microbattery into the sensor. This microbattery will allow for autonomous and continuous measurement of IOP from inside the eye, according to the release. The final product platform will then use smart glasses work by patients for a few minutes each week in order to wirelessly recharge the sensor and uploaded sensor-stored data to a smart phone and cloud platform.¹